AI assistant
CELLULAR GOODS PLC AGM Information 2023
5058_agm-r_2023-02-13_433a57c1-a595-4a06-9578-94b4cae27dad.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 7829P
Cellular Goods PLC
13 February 2023
Press release
13 February 2023
Cellular Goods PLC
('Cellular Goods' or 'the Company')
Results of Annual General Meeting
Cellular Goods (LSE: CBX), a UK-based wellness company providing premium consumer products formulated with lab-produced cannabinoids, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed on a show of hands.
For further information please contact:
| Cellular Goods | |
| Darcy Taylor Chairman and interim CEO Neil Thapar Investor Relations |
via Tancredi +44 207 887 7633 +44 787 645 5323 |
| Tennyson Securities | |
| Corporate Broker & Adviser Peter Krens Alan Howard |
+44 207 186 9030 |
| Novum Securities | |
| Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
| Tancredi Intelligent Communication | |
| Media Relations Helen Humphrey Charlie Hobbs [email protected] |
+44 744 922 6720 +44 789 755 7112 |
About Cellular Goods PLC:
Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Feel Better, Look Better and Function Better. These three verticals encompass Cellular Goods' premium CBG skincare and CBD wellness with the first products launched in December 2021. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGUOSBROWUUAAR